AGL vs. DXRX, VRCI, YGEN, GENI, ABDX, PRM, LLAI, GDR, IDHC, and DMTR
Should you be buying ANGLE stock or one of its competitors? The main competitors of ANGLE include Diaceutics (DXRX), Verici Dx (VRCI), Yourgene Health (YGEN), GENinCode (GENI), Abingdon Health (ABDX), Proteome Sciences (PRM), LungLife AI (LLAI), genedrive (GDR), Integrated Diagnostics (IDHC), and Deepmatter Group (DMTR). These companies are all part of the "diagnostics & research" industry.
Diaceutics (LON:DXRX) and ANGLE (LON:AGL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.
53.1% of Diaceutics shares are held by institutional investors. Comparatively, 27.2% of ANGLE shares are held by institutional investors. 34.5% of Diaceutics shares are held by company insiders. Comparatively, 10.7% of ANGLE shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
ANGLE received 171 more outperform votes than Diaceutics when rated by MarketBeat users. However, 83.33% of users gave Diaceutics an outperform vote while only 62.20% of users gave ANGLE an outperform vote.
In the previous week, Diaceutics had 1 more articles in the media than ANGLE. MarketBeat recorded 1 mentions for Diaceutics and 0 mentions for ANGLE. ANGLE's average media sentiment score of 0.10 beat Diaceutics' score of 0.00 indicating that Diaceutics is being referred to more favorably in the media.
Diaceutics presently has a consensus price target of GBX 150, suggesting a potential upside of 13.21%. ANGLE has a consensus price target of GBX 70, suggesting a potential upside of 273.33%. Given Diaceutics' higher possible upside, analysts plainly believe ANGLE is more favorable than Diaceutics.
Diaceutics has a net margin of 0.03% compared to Diaceutics' net margin of 0.00%. ANGLE's return on equity of 0.01% beat Diaceutics' return on equity.
Diaceutics has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500. Comparatively, ANGLE has a beta of 0.1, meaning that its stock price is 90% less volatile than the S&P 500.
Diaceutics has higher revenue and earnings than ANGLE.
Summary
Diaceutics beats ANGLE on 12 of the 15 factors compared between the two stocks.
Get ANGLE News Delivered to You Automatically
Sign up to receive the latest news and ratings for AGL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
